📣 VC round data is live. Check it out!

Surgical Science Valuation Multiples

Discover Surgical Science's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Deltex Medical Group, InfuSystem, Anika Therapeutics, Sanara MedTech and more.

Surgical Science Overview

About Surgical Science

Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company’s core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.


Founded

1999

HQ

Sweden

Employees

274

Financials (LTM)

Revenue: $108M
EBITDA: $19M

EV

$113M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Surgical Science Financials

Surgical Science reported last 12-month revenue of $108M and EBITDA of $19M.

In the same LTM period, Surgical Science generated $58M in gross profit, $19M in EBITDA, and $9M in net income.

Revenue (LTM)


Surgical Science P&L

In the most recent fiscal year, Surgical Science reported revenue of $109M and EBITDA of $20M.

Surgical Science is profitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 19%, and net margin of 7%.

See analyst estimates for Surgical Science
LTMLast FY202320242025202620272028
Revenue$108M$109M$95M$95M$107M
Gross Profit$58M$71M$66M$64M$71M
Gross Margin54%65%69%68%66%
EBITDA$19M$20M$35M$24M$20M
EBITDA Margin17%19%37%25%19%
EBIT Margin9%7%21%16%7%
Net Profit$9M$7M$25M$14M$7M
Net Margin8%7%27%15%7%

Financial data powered by Morningstar, Inc.

Surgical Science Stock Performance

Surgical Science has current market cap of $185M, and enterprise value of $113M.

Market Cap Evolution


Surgical Science's stock price is $3.62.

Surgical Science share price decreased by 8.7% in the last 30 days, and by 78.1% in the last year.

Surgical Science has an EPS (earnings per share) of $0.14.

See more trading valuation data for Surgical Science
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$113M$185M-4.4%-8.7%9.1%-78.1%$0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Surgical Science Valuation Multiples

Surgical Science trades at 1.0x EV/Revenue multiple, and 6.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Surgical Science

EV / Revenue (LTM)


Surgical Science Financial Valuation Multiples

As of June 3, 2026, Surgical Science has market cap of $185M and EV of $113M.

Surgical Science has a P/E ratio of 21.5x.

LTMLast FY202320242025202620272028
EV/Revenue1.0x1.0x1.2x1.2x1.1x
EV/EBITDA6.1x5.6x3.3x4.7x5.6x
EV/EBIT11.7x14.9x5.6x7.3x15.3x
EV/Gross Profit1.9x1.6x1.7x1.8x1.6x
P/E21.5x25.8x7.4x13.1x25.8x
EV/FCF(141.5x)34.6x5.4x11.8x34.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Surgical Science Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Surgical Science Margins & Growth Rates

Surgical Science decreased revenue by 2% but EBITDA grew by 5% in the last fiscal year.

In the most recent fiscal year, Surgical Science reported gross margin of 65%, EBITDA margin of 19%, and net margin of 7%.

See estimated margins and future growth rates for Surgical Science

Surgical Science Margins

Last FY202420252026202720282029
Gross Margin65%68%66%54%
EBITDA Margin19%25%19%20%
EBIT Margin7%16%7%12%
Net Margin7%15%7%10%
FCF Margin3%10%3%11%

Surgical Science Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(2%)0%12%1%
Gross Profit Growth(19%)(2%)10%(19%)
EBITDA Growth5%(31%)(15%)5%
EBIT Growth65%(24%)(52%)70%
Net Profit Growth51%(44%)(49%)51%
FCF Growth252%(54%)(66%)252%

Data powered by FactSet, Inc. and Morningstar, Inc.

Surgical Science Operational KPIs

Surgical Science's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Surgical Science's Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Surgical Science's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Surgical Science
LTMLast FY202320242025202620272028
Rule of 4021%21%---
Bessemer Rule of X27%21%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue22%22%19%18%19%
G&A Expenses to Revenue10%11%8%6%8%
R&D Expenses to Revenue22%22%21%22%22%
Opex to Revenue-58%48%51%59%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Surgical Science Competitors

Surgical Science competitors include Deltex Medical Group, InfuSystem, Anika Therapeutics, Sanara MedTech, Lucid Diagnostics, Medinice, Asterasys, Aroa Biosurgery, Ilex Medical and RxSight.

Most Surgical Science public comparables operate across Medical Devices, VR & AR, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Deltex Medical Group----
InfuSystem1.4x1.4x6.4x6.3x
Anika Therapeutics1.6x1.5x33.0x24.0x
Sanara MedTech2.2x2.1x13.6x13.7x
Lucid Diagnostics44.1x35.6x(3.7x)(4.0x)
Medinice--(111.9x)-
Asterasys7.5x6.3x22.7x18.2x
Aroa Biosurgery2.8x2.5x81.9x21.4x

This data is available for Pro users. Sign up to see all Surgical Science competitors and their valuation data.

Start Free Trial

Acquisitions by Surgical Science

Surgical Science has acquired 3 companies to date.

Last acquisition by Surgical Science was on July 29th 2021. Surgical Science acquired Simbionix for $305M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Surgical Science

Simbionix
Mimic Technologies
SenseGraphics
Description
Simbionix is a Cleveland-headquartered provider of medical simulation systems for surgical training, offering simulators for laparoscopic, endovascular, endoscopic, bronchoscopy, and endourology procedures. Its Learning Management System tracks trainee performance metrics, while the PROcedure Rehearsal Studio generates patient-specific 3D models from CT scans. Distributed in the Middle East, South America, Asia-Pacific, and Europe, Simbionix serves surgeons, nurses, and technicians globally. Founded in 1997 with R&D in Israel, the company was acquired by 3D Systems in 2016, enhancing VR-based rehearsals for over 1,000 training centers.
Mimic Technologies is a Seattle-headquartered leader in robotic surgery simulation and training. The company supplies software, hardware, and curricula to institutions worldwide, advancing minimally invasive procedures through realistic simulators that enhance surgeon skills and patient safety.
SenseGraphics is a Stockholm-based software platform developer founded in 2004, specializing in H3D API for integrating haptics and 3D stereo visualization into applications. The dual-licensed tool supports X3D and OpenGL standards, compatible with haptic devices from SensAble Technologies, Novint, and Force Dimension. Deployed in medical simulators like MedaPhor ScanTrainer and MOOG Simodont Dental Trainer, as well as veterinary and rehabilitation systems, H3D API facilitates force feedback in research, robotics, and training. SenseGraphics offers consulting, training, and custom hardware alongside its core development toolkit.
HQ CountryUnited StatesUnited StatesSweden
HQ City
Cleveland, OH
Seattle, WA
Stockholm
Deal Date29 Jul 202120 Jan 20211 Jan 2019
Valuation$305M$18M$29M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Surgical Science acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Surgical Science

When was Surgical Science founded?Surgical Science was founded in 1999.
Where is Surgical Science headquartered?Surgical Science is headquartered in Sweden.
How many employees does Surgical Science have?As of today, Surgical Science has over 274 employees.
Who is the CEO of Surgical Science?Surgical Science's CEO is Tom Englund.
Is Surgical Science publicly listed?Yes, Surgical Science is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Surgical Science?Surgical Science trades under SUS ticker.
When did Surgical Science go public?Surgical Science went public in 2017.
Who are competitors of Surgical Science?Surgical Science main competitors include Deltex Medical Group, InfuSystem, Anika Therapeutics, Sanara MedTech, Lucid Diagnostics, Medinice, Asterasys, Aroa Biosurgery, Ilex Medical, RxSight.
What is the current market cap of Surgical Science?Surgical Science's current market cap is $185M.
What is the current revenue of Surgical Science?Surgical Science's last 12 months revenue is $108M.
What is the current revenue growth of Surgical Science?Surgical Science revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Surgical Science?Current revenue multiple of Surgical Science is 1.0x.
What is the current EBITDA of Surgical Science?Surgical Science's last 12 months EBITDA is $19M.
What is Surgical Science's EBITDA margin?Surgical Science's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Surgical Science?Current EBITDA multiple of Surgical Science is 6.1x.
What is the current FCF of Surgical Science?Surgical Science's last 12 months FCF is ($801K).
What is Surgical Science's FCF margin?Surgical Science's last 12 months FCF margin is (1%).
What is the current EV/FCF multiple of Surgical Science?Current FCF multiple of Surgical Science is (141.5x).
How many companies Surgical Science has acquired to date?As of June 2026, Surgical Science has acquired 3 companies.
What was the largest acquisition by Surgical Science?$305M acquisition of Simbionix on 29th July 2021 was the largest M&A Surgical Science has done to date.
What companies Surgical Science acquired?Surgical Science acquired Simbionix, SenseGraphics, and Mimic Technologies.
In how many companies Surgical Science has invested to date?Surgical Science hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Surgical Science

Lists including Surgical Science

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial